The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1327
December 14, 2009
View Complete Issue         Table of Contents 2019 
Ophthalmic Besifloxacin (Besivance)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ophthalmic Besifloxacin (Besivance)
December 14, 2009 (Issue: 1327)
The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension (Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the manufacturer, this product was developed...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ophthalmic Besifloxacin (Besivance)
Article code: 1327e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.